Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 29 May 2025. Alzamend Neuro (NASDAQ: ALZN) reported that the initial subject in the Phase II “Lithium-in-Brain” trial has received its dosage of AL001 for comparison against lithium carbonate. The study’s primary findings are antic Revelation Biosciences (NASDAQ: REVB) priced a US$4m public offering of 3.64m shares (or equivalents) and warrants for up to 14.56m shares at US$1.10 per share and warrant. Warrants are exercisable at US$1.10 upon stoc IMUNON (NASDAQ: IMNN) completed a US$3.25m private placement by selling 7,222,223 common shares and short-term warrants for an additional 14,444,446 shares at US$0.45 per share. The warrants could generate up to US$6.5 Applied DNA Sciences (NASDAQ: APDN) will implement a 1‑for‑15 reverse stock split effective 2 June 2025. Shares closed down 37% at US$0.33. Intensity Therapeutics (NASDAQ: INTS) will showcase a Trials‑in‑Progress poster on its Phase 3 INVINCIBLE‑3 study of intratumoral INT230‑6 in metastatic soft‑tissue sarcoma at ASCO 2025. Shares closed up 34% at US$0.39 ORIC Pharmaceuticals (NASDAQ: ORIC) reported Phase 1b data for ORIC-944 in mCRPC, with 59% PSA50 and 24% PSA90 confirmed response rates. They also secured approximately US$125m via a private placement at US$6.50 per sh Immunic (NASDAQ: IMUX) announced the pricing of a public offering including pre-funded warrants exercisable immediately, Series A warrants exercisable until 31 December 2025, and Series B warrants exercisable starting Intellia Therapeutics (NASDAQ: NTLA) shares are currently down during premarket hours after reporting a Grade 4 liver enzyme elevation in a patient in the late-stage MAGNITUDE trial for its Regeneron (NASDAQ: REGN)-par